MARLBOROUGH, Mass. and YOKNEAM
ILIT, Israel, July 25, 2017 /PRNewswire/ -- An in-depth
story in TechCrunch covers the recent public debut of Restore, the
new soft suit exoskeleton created in collaboration by ReWalk
Robotics Ltd. (Nasdaq: RWLK) ("ReWalk") and Harvard University's Wyss Institute for
Biologically Inspired Engineering.
ReWalk and the Wyss Institute provided the first public
demonstration of the Restore prototype at the MassRobotics event
held on the campus of the Massachusetts
Institute of Technology (MIT)
earlier this month. Restore is a soft suit exoskeleton system
intended to assist stroke survivors. The TechCrunch piece
explains in detail how the device works:
"The device…relies on a motor built into a waistband that
controls a pair of cables that operate similarly to bicycle brakes,
lifting a footplate in the shoe and moving the whole leg in the
process. The unaffected leg, meanwhile, has sensors that measure
the wearer's gait while walking, syncing up the two legs' movement.
An able-bodied representative from Harvard was on-hand at the event, demonstrating how
the system automatically adjusts when walking at different
speeds."
ReWalk and Wyss premiered the Restore prototype on Yahoo Finance
in June.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable
robotic exoskeletons for individuals with spinal cord injury. Our
mission is to fundamentally change the quality of life for
individuals with lower limb disability through the creation and
development of market leading robotic technologies. Founded in
2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk
systems, please visit www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in
Israel.
Forward-Looking Statements
In addition to historical information, this press release contains
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995, Section 27A of the U.S.
Securities Act of 1933, and Section 21E of the U.S. Securities
Exchange Act of 1934. Such forward-looking statements may include
projections regarding ReWalk's future performance and, in some
cases, may be identified by words like "anticipate," "assume,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "plan," "potential," "predict," "project," "future," "will,"
"should," "would," "seek" and similar terms or phrases. The
forward-looking statements contained in this press release are
based on management's current expectations, which are subject to
uncertainty, risks and changes in circumstances that are difficult
to predict and many of which are outside of ReWalk's control.
Important factors that could cause ReWalk's actual results to
differ materially from those indicated in the forward-looking
statements include, among others: ReWalk's expectations regarding
future growth, including its ability to increase sales in its
existing geographic markets, expand to new markets and achieve its
planned expense reductions; the conclusion of ReWalk's management
for the financial statements for fiscal 2016 and the first quarter
of 2017, and the opinion of ReWalk's auditors in their report on
the Company's financial statements for fiscal 2016, that there are
substantial doubts as to ReWalk's ability to continue as a going
concern; ReWalk's ability to maintain and grow its reputation and
the market acceptance of its products; ReWalk's ability to achieve
reimbursement from third-party payors for its products; ReWalk's
expectations as to its clinical research program and clinical
results; ReWalk's expectations as to the results of, and the Food
and Drug Administration's potential regulatory developments with
respect to, ReWalk's mandatory post-market 522 surveillance study;
the outcome of ongoing shareholder class action litigation relating
to ReWalk's initial public offering; ReWalk's ability to repay its
secured indebtedness; ReWalk's ability to improve its products and
develop new products; ReWalk's ability to maintain adequate
protection of its intellectual property and to avoid violation of
the intellectual property rights of others; ReWalk's ability to
gain and maintain regulatory approvals; ReWalk's ability to secure
capital from its at-the-market equity distribution program based on
the price range of its ordinary shares and conditions in the
financial markets; ReWalk's ability to use effectively the proceeds
of its 2016 follow-on offering; ReWalk's ability to maintain
relationships with existing customers and develop relationships
with new customers; and other factors discussed under the heading
"Risk Factors" in ReWalk's Annual Report on Form 10-K for the year
ended December 31, 2016, as amended,
filed with the U.S. Securities and Exchange Commission and other
documents subsequently filed with or furnished to the U.S.
Securities and Exchange Commission. Any forward-looking statement
made in this press release speaks only as of the date hereof.
Factors or events that could cause ReWalk's actual results to
differ from the statements contained herein may emerge from time to
time, and it is not possible for ReWalk to predict all of them.
Except as required by law, ReWalk undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future developments or otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/icymi-techcrunch-features-restore-soft-suit-showcase-at-mits-massrobotics-event-300493426.html
SOURCE ReWalk Robotics Ltd.